UPDATE: Oppenheimer Upgrades DexCom (DXCM) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Canaccord Genuity Reiterates Buy on DexCom (DXCM) Following FDA Approval of DexCom's G5 Mobile
December 21, 2016 10:17 AM ESTCanaccord Genuity reiterated a Buy rating and $70.00 price target on DexCom (NASDAQ: DXCM) following the company's announced FDA approval of DexCom's G5 mobile for "non-adjunctive use". Notably, the FDA stated that although G5 "still requires two finger-stick calibrations, it eliminates the need for any additional finger-stick blood... More
